BR9604882A - Terapia de combinação de inibidor de enzima de conversão de antgiotensina e quantidade de efeito colateral reduzido de antagonista de aldosterona para tratamento de doença cardiovascular - Google Patents

Terapia de combinação de inibidor de enzima de conversão de antgiotensina e quantidade de efeito colateral reduzido de antagonista de aldosterona para tratamento de doença cardiovascular

Info

Publication number
BR9604882A
BR9604882A BR9604882A BR9604882A BR9604882A BR 9604882 A BR9604882 A BR 9604882A BR 9604882 A BR9604882 A BR 9604882A BR 9604882 A BR9604882 A BR 9604882A BR 9604882 A BR9604882 A BR 9604882A
Authority
BR
Brazil
Prior art keywords
treatment
amount
side effect
combination therapy
cardiovascular disease
Prior art date
Application number
BR9604882A
Other languages
English (en)
Inventor
Todd E Maclaughlan
Alfonso T Perez
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of BR9604882A publication Critical patent/BR9604882A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BR9604882A 1995-02-10 1996-02-09 Terapia de combinação de inibidor de enzima de conversão de antgiotensina e quantidade de efeito colateral reduzido de antagonista de aldosterona para tratamento de doença cardiovascular BR9604882A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38685295A 1995-02-10 1995-02-10
PCT/US1996/001969 WO1996024373A2 (en) 1995-02-10 1996-02-09 Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist

Publications (1)

Publication Number Publication Date
BR9604882A true BR9604882A (pt) 1998-05-19

Family

ID=23527334

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9604882A BR9604882A (pt) 1995-02-10 1996-02-09 Terapia de combinação de inibidor de enzima de conversão de antgiotensina e quantidade de efeito colateral reduzido de antagonista de aldosterona para tratamento de doença cardiovascular

Country Status (13)

Country Link
EP (2) EP1136078A3 (pt)
JP (1) JPH11507012A (pt)
KR (1) KR19980702099A (pt)
AT (1) ATE243529T1 (pt)
AU (1) AU5354196A (pt)
BR (1) BR9604882A (pt)
CA (1) CA2212713A1 (pt)
DE (1) DE69628821T2 (pt)
DK (1) DK0808172T3 (pt)
ES (1) ES2205023T3 (pt)
NZ (1) NZ305528A (pt)
PT (1) PT808172E (pt)
WO (1) WO1996024373A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69808518T2 (de) * 1997-12-23 2003-06-26 Warner Lambert Co Ace hemmer/matrix metalloproteinase hemmer-arzneimittelkombinationen
DK1121111T3 (da) 1998-10-15 2010-05-31 Imp Innovations Ltd Forbindelser til behandling af vægttab
US6410524B1 (en) 1998-11-06 2002-06-25 G. D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
WO2001080895A2 (en) * 2000-04-26 2001-11-01 First Horizon Pharmaceutical Corporation Methods and compositions for the treatment of cardiac indications
US20050014732A1 (en) * 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CN106018820B (zh) 2006-08-04 2018-04-27 汉诺威医学院 根据gdf-15评价心脏介入风险的工具与方法
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
CA2756779C (en) * 2009-03-26 2019-10-29 Ajay Gupta Compositions and methods for treatment of renal disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
WO1995009625A1 (en) * 1993-10-04 1995-04-13 Handforth Investments Ltd. Use of amiodarone for the treatment of heart failure

Also Published As

Publication number Publication date
EP0808172B1 (en) 2003-06-25
ATE243529T1 (de) 2003-07-15
ES2205023T3 (es) 2004-05-01
WO1996024373A2 (en) 1996-08-15
EP1136078A3 (en) 2002-07-24
DK0808172T3 (da) 2003-10-20
WO1996024373A3 (en) 1996-09-26
EP1136078A2 (en) 2001-09-26
KR19980702099A (ko) 1998-07-15
JPH11507012A (ja) 1999-06-22
CA2212713A1 (en) 1996-08-15
NZ305528A (en) 2001-05-25
DE69628821T2 (de) 2004-05-06
PT808172E (pt) 2003-11-28
AU5354196A (en) 1996-08-27
DE69628821D1 (de) 2003-07-31
EP0808172A2 (en) 1997-11-26

Similar Documents

Publication Publication Date Title
BR9915134A (pt) Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição
CA2282654A1 (en) Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder
NZ336568A (en) Photochemotherapeutic compositions
AU3920900A (en) Compounds and methods to treat cardiac failure and other disorders
AU579595B2 (en) Enzyme-resistant immunomodulatory peptides
MY121008A (en) Combination therapy comprising atorvastatin and an antihypertensive agent.
BR9604882A (pt) Terapia de combinação de inibidor de enzima de conversão de antgiotensina e quantidade de efeito colateral reduzido de antagonista de aldosterona para tratamento de doença cardiovascular
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
HK1019856A1 (en) Therapeutic uses of bpi protein products for human meningococcemia
MXPA01009035A (es) Terapia de combinacion de inhibidor de enzima convertidora de angiotensina y antagonista de aldosterona epoxi-esteroidea para tratamiento de enfermedad cardiovascular.
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
EP0220107A3 (en) Use of angiotensin-converting enzyme inhibitors in macular degeneration
IL139748A0 (en) Heterocyclic compounds and methods to treat cardiac failure and other disorders
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
EP1201248A3 (en) Combination therapy of angiotensin converting enzyme inhibitor, side-effect reduced amount of aldosterone antagonist and diuretic for treatment of cardiovascular disease
AU5558498A (en) Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
WO2001046405A3 (en) Modulation of pax-2 for controlled apoptosis or survival of cells
AR021106A1 (es) Terapia combinada de un inhibidor de la enzima convertidora de angiotensina y un antagonista de aldosterona para reducir la morbilidad y mortalidad porenfermedades cardiovasculares
DE59409746D1 (de) Verwendung von lithiumverbindungen zur behandlung von herzinsuffizienz
MXPA02004704A (es) Analogos de acido hidroxieicosatetraenoico y sus metodos de uso en el tratamiento de trastornos de resequedad del ojo.
薬袋一夫 Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors.
IT1312003B1 (it) Uso di lonidamina e suoi derivati nel trattamento di affezioni causateda retrovirus.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO, DE ACORDO COM ARTIGO 8O DA LPI